Evidence map›Paper›PMID 40678315›Full record

ReviewFrontiers in endocrinology2025

Prolonged post-androgen abuse hypogonadism: potential mechanisms and a proposed standardized diagnosis.

Joël van Os, Diederik Laurens Smit, Peter Bond, Willem de Ronde

Abstract readReview
In one paragraph

Review in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Joël van OsSpaarne Gasthuis, Department of Internal Medicine, Haarlem, Netherlands.
Diederik Laurens SmitAndroid Health Clinic, Department of Performance and Image-enhancing Drugs Research, Utrecht, Netherlands.
Peter BondAndroid Health Clinic, Department of Performance and Image-enhancing Drugs Research, Utrecht, Netherlands.
Willem de RondeSpaarne Gasthuis, Department of Internal Medicine, Haarlem, Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Androgen abuse, which is increasingly prevalent, inevitably leads to suppression of the hypothalamic-pituitary-gonadal axis (HPGA). While most individuals recover HPGA function following androgen cessation, a subset experiences prolonged hypogonadism, with symptoms persisting for months or even years. Currently, this condition lacks a standardized definition, complicating both diagnosis and treatment. In this article, we explore the potential mechanisms underlying prolonged hypogonadism after androgen abuse, including the role of prolonged androgen activity, hypothalamic-pituitary alterations, testicular changes, suppression of sex hormone-binding globulin (SHBG), genetic predisposition, and undisclosed ongoing androgen abuse. We propose the term 'Prolonged Post-Androgen Abuse Hypogonadism'(PPAAH) to standardize diagnosis and guide future research. PPAAH is provisionally defined as persistent hypogonadism six months after cessation of androgen abuse, in individuals with a cumulative androgen exposure of at least 150 mg per week for a minimum of six months. Diagnosing PPAAH requires excluding other causes of hypogonadism. This preliminary framework is intended to support further research into the pathophysiology and management of this condition, and may require refinement as further evidence emerges.

Indexed as

AndrogensHypogonadismSubstance-Related DisordersHumansHypothalamo-Hypophyseal SystemMaleAndrogensanabolic-androgenic steroidsanabolic steroid abuseandrogen abuseendocrine disruptionHPGA recoveryhypogonadismtestosterone (androgen)

Identifiers

PMID40678315
PMCPMC12267013

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.